Dosimetric impact of 3D motion-compensated SPECT reconstruction for SIRT planning

EJNMMI Physics

Table 3 Activities to be prescribed for each patient and each reconstruction (3D and 3Dcomp) estimated from international recommendations [10, 34]

Number of patient	Activity in GBq (3D)	Activity in GBq (3Dcomp)	Recommended dose tolerance limit reached	Relative difference between 3D and 3Dcomp (%)
1	4.263	4.298	Normal liver dose	0.8
7	2.470	2.538	Normal liver dose	2.8
9	13.651	13.051	Normal liver dose	− 4.4
10	1.632	1.496	Normal liver dose	− 8.3
11	1.312	1.362	Tumor dose	3.8
13	6.604	6.582	Normal liver dose	− 0.3
15	3.525	3.553	Normal liver dose	0.8
16	2.907	2.907	Normal perfused liver dose	0
17	4.510	4.495	Normal liver dose	− 0.3
18	1.280	1.572	Tumor dose	22.8
19	2.514	2.530	Normal perfused liver dose	0.6
20	2.324	2.450	Tumor dose	5.4
22	1.202	1.219	Normal liver dose	1.4
23	5.077	5.076	Normal liver dose	0.0
24	5.793	5.907	Normal liver dose	2.0
25	1.227	1.194	Normal perfused liver dose	− 2.7
26	4.694	4.560	Normal liver dose	− 2.9
27	4.251	4.262	Normal liver dose	0.3
28	3.459	3.419	Normal liver dose	− 1.2
29	2.354	2.372	Normal liver dose	0.8

The relative difference of dose was also computed. The criterion corresponded to the limit that led to the choice of this activity to prescribe